A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Recent clinical trials have demonstrated targeting PI3K pathway is a promising strategy for the treatment of blood cancers. To identify novel PI3K inhibitors, we performed a high throughput virtual screen and identified several novel small molecule compounds, including PIK-C98 (C98). The cell-free e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zhu, Jingyu, Wang, Man, Yu, Yang, Qi, Huixin, Han, Kunkun, Tang, Juan, Zhang, Zubin, Zeng, Yuanying, Cao, Biyin, Qiao, Chunhua, Zhang, Hongjian, Hou, Tingjun, Mao, Xinliang
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381587/
https://ncbi.nlm.nih.gov/pubmed/25474140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados